Apatinib With Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma Of The Stomach
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
Gastric cancer is a highly heterogeneous tumor. The most commonly used clinical
classifications of gastric cancer are Lauren classification (intestinal, diffuse, mixed) and
World Health Organization(WHO) classification (papillary adenocarcinoma, tubular
adenocarcinoma, mucinous glands cancer and low-adhesion cancer). Hepatoid adenocarcinoma of
the stomach (HAS) is a special and rare type of gastric cancer.
Compared with ordinary gastric cancer, HAS has unique clinicopathological characteristics,
prone to liver metastasis and lymph node metastasis, has a highly aggressive and malignant
biological behavior, a worse prognosis than alpha fetoprotein(AFP) normal gastric cancer, and
is easily confused with hepatocellular carcinoma(HCC). There is the possibility of
misdiagnosis and mistreatment, so it has gradually attracted people's attention. Most of the
domestic and foreign literature on HAS in the past 30 years are retrospective cases or small
sample reports, and there are few prospective studies. There is no standard treatment plan
for HAS. The main treatment is based on gastric adenocarcinoma. The clinical treatment
principle is a comprehensive treatment plan with surgical resection as the mainstay,
supplemented by systemic chemotherapy and local interventional therapy. This type of gastric
cancer has a relatively high degree of malignancy, rapid progress of the disease, and easy
recurrence after surgery. There is no standard treatment plan in China and other foreign
countries.
The aim of this study was to evaluate the efficacy and safety of apatinib with oxaliplatin
and S-1 treatment advanced hepatoid adenocarcinoma of the stomach.